Comparison of HBeAg clearance rates between tenofovir alafenamide and entecavir in treatment-naive HBeAg positive chronic hepatitis B patients over 48 to 96 weeks: A retrospective cohort study
For HBeAg-positive CHB patients, TAF demonstrated superior efficacy to ETV in achieving HBeAg clearance over 48-96 weeks. This effect was more pronounced in patients with lower baseline qHBeAg levels or already existing anti-HBe positivity.
Authors
- Yulun Tang (ORCID: https://orcid.org/0000-0003-1002-3663)
- Yuliang Zhang (ORCID: https://orcid.org/0000-0002-9413-0900)
- Shanfei Ge
- Shipeng Ma
- Lajpat Rai Malhi
- Qian Liu
- Liang Wang
- Xin Wan
Publication Details
- Journal
- Digestive Diseases
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1159/000550770
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00